首页> 外文OA文献 >Changes in serum C-PTH, serum ALP, and subjective symptoms during oral 1.ALPHA., 25(OH)2D3 pulse therapy and conventional therapy in hemodialysis patients with secondary hyperparathyroidism.

【2h】

Changes in serum C-PTH, serum ALP, and subjective symptoms during oral 1.ALPHA., 25(OH)2D3 pulse therapy and conventional therapy in hemodialysis patients with secondary hyperparathyroidism.

机译：口服血清C-PTH，血清ALP，血清ALP和主观症状的变化。，25（OH）2D3脉冲治疗和血液透析患者的常规治疗继发性甲状旁腺功能亢进。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Toru Hyodo; Koji Ono; Tsutomu Koumi; Masanobu Ueda; Ikuo Miyagawa; Yoshiko Kitamoto; Tomohiro Izumi; Noriaki Tanaka;
展开▼
作者单位

展开▼
年度 1991
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. [J] . Strozecki P, Kretowicz M, Odrowaz Sypniewska G, Renal failure. . 2004,第4期

机译：静脉1,25（OH）2D3治疗对继发性甲状旁腺功能亢进的血液透析患者葡萄糖代谢的影响。
2. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. [J] . Oyama Y, Kazama JJ, Omori K, Clinical and experimental nephrology . 2005,第2期

机译：对于患有继发性甲状旁腺功能亢进症的透析患者，预处理血浆中完整的甲状旁腺激素和血清钙水平，而不是血清磷酸盐水平可预测对马沙骨化醇治疗的反应。
3. Impact of a single oral dose of 100,000 IU vitamin D3 on profiles of serum 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 in adults with vitamin D insufficiency [J] . LanjaSaleh, JonathanTang, JoannaGawinecka, Clinical chemistry and laboratory medicine: CCLM . 2017,第12期

机译：单个口服剂量为100,000 IU维生素D3对血清25（OH）D3及其代谢物24,25（OH）2D3，3-EPI-25（OH）D3和1,25（OH）2D3的曲线的影响成年人维生素D功能不全
4. Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels [C] . Masaki Ohya, Mitsuru Yashiro, Tomohiro Sonou, Nihon To?seki Igakkai., Gakujutsu Shu?kai So?kai . 2018

机译：静脉内的Maxacalcitol治疗与血液透析患者的血清成纤维细胞生长因子23水平与血清磷酸盐或钙水平无关相关
5. FACTORS AFFECTING SERUM LIPID LEVELS IN RENAL PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS OR CONTINUOUS AMBULATORY PERITONEAL DIALYSIS TREATMENTS (DISEASE, DIET THERAPY). [D] . SALTOS, ETTA ANGEL. 1985

机译：正在进行维持性血液透析或连续性非循环性腹膜透析治疗（疾病，饮食疗法）的肾病患者血清脂水平的影响因素。
6. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders [O] . Kazuya Takasawa, Chikako Takaeda, Takashi Wada, 2018

机译：日本血液透析轻度炎症患者的最佳血清铁蛋白水平用于口服铁疗法（OIT）时的铁缺乏性贫血以及对OIT无反应者进行静脉铁疗法的益处
7. Variations in circulating 1,25(OH)2D3 levels after oral intake of 1.ALPHA.(OH)D3 at 8.MU.g in two patients with chronic renal failure. [O] . Yoshihiro Motomiya, Katsunori Yoshida, Yoshiteru Kaneko, 1990

机译：口服摄入1,25（OH）2D3水平的循环1,25（OH）2D3水平的变化。（OH）D3在8例慢性肾功能衰竭患者中。

Changes in serum C-PTH, serum ALP, and subjective symptoms during oral 1.ALPHA., 25(OH)2D3 pulse therapy and conventional therapy in hemodialysis patients with secondary hyperparathyroidism.

著录项

引文网络

相似文献

相关主题

期刊订阅